scholarly journals Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis

2020 ◽  
Vol 11 (12) ◽  
pp. 3536-3546
Author(s):  
Shuang Zhang ◽  
Shuang Li ◽  
Ying Cheng
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Stage ◽  
First Line Treatment

Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer – a meta-analysis

Immunotherapy ◽  
2021 ◽  
Author(s):  
Ching-Yi Chen ◽  
Wang-Chun Chen ◽  
Chao-Ming Hung ◽  
Yu-Feng Wei
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Stage ◽  
First Line Treatment

This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). Seven randomized controlled trials with a total of 2862 patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy provided a better progression-free survival (PFS) with a hazard ratio (HR) of 0.81, p < 0.00001, and overall survival (OS) with a HR of 0.82, p < 0.0001; however, the incidence of treatment-related adverse effects (TRAEs) was significantly increased. Subgroup analyses showed that good performance status, cisplatin-based chemotherapy, without brain metastases at baseline and non-Asian populations were associated with greater benefits in OS from chemo-immunotherapy. Chemo-immunotherapy demonstrated better PFS and OS compared with chemotherapy alone as first line treatment in ES-SCLC, but additional TRAEs should be closely monitored.

Sign in / Sign up

Export Citation Format

Share Document